TABLE 6.
Ongoing clinical trials investigating drugs for AD.
| Drugs | Therapeutic purpose | Company | Trial | Clinical trial ID | Status |
|---|---|---|---|---|---|
| Donanemab | Anti-amyloid-therapy | Eli Lilly & Co | TRAILBLAZERALZ 2 (Phase 3) | NCT04437511 | Active, not recruiting |
| Donanemab | Anti-amyloid-therapy | Eli Lilly & Co | TRAILBLAZER-ALZ 3 (Phase 3) | NCT05026866 | Recruiting |
| Donanemab/Aducanumab | Anti-amyloid-therapy | Eli Lilly & Co | TRAILBLAZER-ALZ 4 (Phase 3) | NCT05108922 | Active, not recruiting |
| Simufilam | Anti-amyloid-therapy | Cassava Sciences | RETHINK-ALZ (Phase 3) | NCT04994483 | Recruiting |
| Simufilam | Anti-amyloid-therapy | Cassava Sciences | REFOCUS-ALZ (Phase 3) | NCT05026177 | Recruiting |
| CT1812 | Anti-amyloid-therapy | Cognition Therapeutics | SHINE (COG0201) (Phase 2) | NCT03507790 | Recruiting |
| CT1812 | Anti-amyloid-therapy | Cognition Therapeutics | START (COG0203) (Phase 2) | NCT05531656 | Recruiting |
| BIIB080 | Anti-tau DNA/RNA-based therapy | Biogen, IONIS Pharmaceuticals | CELIA | NCT05399888 | Recruiting |
| Bepranemab | Anti-tau DNA/RNA-based therapy | Hoffmann-La Roche | Phase 2 | NCT04867616 | Active, not recruiting |
Reference: Huang et al. (2023).